Free Exhibit to a Document - District Court of Delaware - Delaware

Case 1:08-cv-00126-SLR Document 20 Filed 05/15/2008 Page 1 013

Case 1 :08-cv-00126-SLR Document 20 Filed 05/15/2008 Page 2 of 3
Exhibit 99.1
lnvestor Relations:
Christopher Taylor
78l-398-2466
Media Relations:
Sarah Emond
78l—398-2544
F gr Immggiatg Bglgasg
Oscient Pharmaceuticals Provides Preliminary Revenue Results for First Quarter 2008
— ANTARA posts strong prescription growth;
Company on track to meet 2008 revenue guidance of approximately $100 million —
Waltham, Mass., April 16, 2008 — OscientPham1aceuticals Corporation (Nasdaq: OSCl) today announced preliminary revenue results for the first quarter
ended March 3 l , 2008. For the first quarter gf 2008, the Company expects to record total revenues of approximately $l 8.5 million, with more than
two-thirds derived from sales of ANTARA (fenofibrate) capsules. The Company expects its total cash, including restricted cash and cash equivalents, as
of March 3 l, 2008, to be approximately $42 million.
"While quarterly revenues fluctuate due to the timing of shipments and wholesaler buying pattems, as well as the seasonality of FACTIVE, we remain on
track to achieve our previously provided 2008 guidance," stated Steven M. Rauscher, President and Chief Executive Officer. "ANTARA prescriptions
increased more than 30% in the first quarter of 2008 compared to the first quarter of 2007 and weekly prescriptions continued to grow to record highs.
Further positive initiatives in managed care and physician targeting will support the continued growth of ANTARA, which the Company expects to account
for 75% of 2008 revenues."
The Company reiterates its previously announced guidance of $96—$l 03 million in revenues from ANTARA and FACTIVE ® (gemifloxacin mesylate)
tablets in 2008 and $28—$3O million in net cash utilization. This guidance does not include the potential cash impact of the acquisition and marketing of a
third product, which remains one of the Company’s business development goals.
The Company plans to announce complete financial results and host a conference call with investors on May 7, 2008.
About Oscient Pharmaceuticals
Oscient Pharmaceuticals Corporation is a commercial—stage pharmaceuticakcompany marketing two FDA—approved products in the United States:
ANTARA (fenofibrate) capsules, a cardiovascular product and FACTIVE (gemifloxacin mesylate) tablets, a fluoroquinolone antibiotic. ANTARA is
indicated for the adjunct treatment of hypercholesterolemia (high blood cholesterol) and hypertriglyceridemia (high triglycerides) in combination with diet.
FACTIVE is approved for the treatment of acute bacterial exacerbations of chronic bronchitis and community-acquired pneumonia of mild to moderate
severity. Oscient promotes ANTARA and FACTIVE through a national sales force calling on primary care physicians, cardiologists, endocrinologists and
pulmonologists. The Company also has a novel, late—stage antibiotic candidate, Ramoplanin, for the treatment of Clostridium dWicile—associated disease
(CDAD).
For important information regarding the safety and use of ANTARA and FACTIVE, please see the fi1ll prescribing information available at
and
—more—

Case 1 :08-cv-00126-SLR Document 20 F1 led 05/15/2008 Page 3 of 3

Q1 2008 Preliminary Results
April 16, 2008
Page 2 of 2
F0rward—L00king Statement
This news release contains hrward—looking statements made pursuant to the safe harbor provisions ofthe Private Securities Litigation Reform Act of
1995, including statements with regard to H) preliminary 2008 first quarter financial results and the relative contribution ofthe Company 's products to
such preliminary financial results, (ii) the Company is expected cash balances as of March 31, 2008, Uii) the Company Ks anticipated total revenue and net
cash utilization for the 2008 fiscal year, and (iv) the continued growth ofthe Company ’s products in 2008. F orward·looking statements represent our
management 's judgment regarding juture events. F orward-looking statements typicalbr are identyied by use of terms such as “may, " “will, " "shoulal "
‘plan, " "expect, " "intenal " "anticqzate, " "estimate, " and similar words, although some forward-·looking statements are expressed dyferentbt. We do not
plan to update these forward-looking statements. You should be aware that our actual results could dwer materialbrjrom those contained in the
forward—looking statements due to a number of risks ajjecting our business. These risks include, but are not limited to (a) our ability to successfulbr
commercialize and market ANTARA or FAC TI VE due to: the limitations on our resources and experience in the commercialization of products; lack of
acceptance by physicians, patients and thirdparty payors; unanticqzated safety, product liability, ejicacy, or other regulatory issues; delays in recruiting
and training sales personnel; problems relating to manufacturing or suppbr; delays in the supph: of products by the thirdparty manufacturers and suppliers
on which we rely; inadequate distribution ofthe products by wholesalers, pharmacies, hospitals and other customers; and competition jrom other products;
(b) the delay in or inability to obtain additional regulatory approvals of our products and product candidates due to negative, inconclusive or insujicient
results in ongoing or future clinical trials, the FDA or EMEA requiring additional information or data, delays in the progress of ongoing clinical trials,
safety concerns arising with respect to our products or product candidates and disputes with the third parties from whom we license our products or
product candidates; (c) delays by the FDA or EMEA; and (ay claims against us by third parties, including claims relating to our intellectual property
position. Factors that could cause actual results to dwer materialbrfom those projected or suggested in any forward- looking statement are described
under the heading "Risk Factors " in the Company ’s Annual Report on Form l0·K for the year ending December 31, 2007 and in other filings that we may
make with the Securities and Exchange Commission jrom time to time.
###

Case 1:08-cv-00126-SLR

Document 20

Filed 05/15/2008

Page 1 of 3

Case 1:08-cv-00126-SLR

Document 20

Filed 05/15/2008

Page 2 of 3

Case 1:08-cv-00126-SLR

Document 20

Filed 05/15/2008

Page 3 of 3